vs
Side-by-side financial comparison of Blue Bird Corp (BLBD) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Blue Bird Corp is the larger business by last-quarter revenue ($333.1M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). Blue Bird Corp runs the higher net margin — 9.2% vs 1.6%, a 7.6% gap on every dollar of revenue. On growth, Blue Bird Corp posted the faster year-over-year revenue change (6.1% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -1.9%).
The Blue Bird Corporation is an American bus manufacturer. Headquartered in Fort Valley, Georgia, the company was best known for its production of school buses. The company has also manufactured a wide variety of other bus types, including transit buses, motorhomes, and specialty vehicles such as mobile libraries and mobile police command centers.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BLBD vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $333.1M | $177.4M |
| Net Profit | $30.8M | $2.9M |
| Gross Margin | 21.4% | — |
| Operating Margin | 11.3% | 3.9% |
| Net Margin | 9.2% | 1.6% |
| Revenue YoY | 6.1% | 5.0% |
| Net Profit YoY | 7.1% | — |
| EPS (diluted) | $0.94 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $333.1M | $196.9M | ||
| Q3 25 | $409.4M | $179.5M | ||
| Q2 25 | $398.0M | $181.1M | ||
| Q1 25 | $358.9M | $168.9M | ||
| Q4 24 | $313.9M | $187.3M | ||
| Q3 24 | $350.2M | $168.6M | ||
| Q2 24 | $333.4M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $30.8M | — | ||
| Q3 25 | $36.5M | $5.4M | ||
| Q2 25 | $36.5M | $-4.8M | ||
| Q1 25 | $26.0M | $4.8M | ||
| Q4 24 | $28.7M | — | ||
| Q3 24 | $24.7M | $-143.5M | ||
| Q2 24 | $28.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | 79.5% | ||
| Q3 25 | 21.1% | 80.9% | ||
| Q2 25 | 21.6% | 77.4% | ||
| Q1 25 | 19.7% | 79.7% | ||
| Q4 24 | 19.2% | 78.7% | ||
| Q3 24 | 17.0% | 76.9% | ||
| Q2 24 | 20.8% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 11.3% | 1.2% | ||
| Q3 25 | 12.3% | 3.5% | ||
| Q2 25 | 12.6% | 4.7% | ||
| Q1 25 | 9.4% | 1.2% | ||
| Q4 24 | 10.5% | 13.2% | ||
| Q3 24 | 7.3% | -82.8% | ||
| Q2 24 | 11.9% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 9.2% | — | ||
| Q3 25 | 8.9% | 3.0% | ||
| Q2 25 | 9.2% | -2.7% | ||
| Q1 25 | 7.3% | 2.8% | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 7.0% | -85.1% | ||
| Q2 24 | 8.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.94 | $0.05 | ||
| Q3 25 | $1.11 | $0.12 | ||
| Q2 25 | $1.12 | $-0.11 | ||
| Q1 25 | $0.79 | $0.10 | ||
| Q4 24 | $0.86 | $0.38 | ||
| Q3 24 | $0.71 | $-3.11 | ||
| Q2 24 | $0.85 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $241.7M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $271.4M | $653.9M |
| Total Assets | $642.3M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $241.7M | $238.4M | ||
| Q3 25 | $229.3M | $246.3M | ||
| Q2 25 | $173.1M | $445.9M | ||
| Q1 25 | $130.7M | $493.6M | ||
| Q4 24 | $136.1M | $484.6M | ||
| Q3 24 | $127.7M | $453.8M | ||
| Q2 24 | $88.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $271.4M | $693.1M | ||
| Q3 25 | $255.4M | $727.2M | ||
| Q2 25 | $221.8M | $757.8M | ||
| Q1 25 | $190.4M | $798.5M | ||
| Q4 24 | $179.7M | $778.3M | ||
| Q3 24 | $159.6M | $749.6M | ||
| Q2 24 | $137.3M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $642.3M | $1.3B | ||
| Q3 25 | $625.3M | $1.3B | ||
| Q2 25 | $575.5M | $1.5B | ||
| Q1 25 | $543.7M | $1.6B | ||
| Q4 24 | $535.2M | $1.6B | ||
| Q3 24 | $524.9M | $1.5B | ||
| Q2 24 | $468.1M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $36.6M | — |
| Free Cash FlowOCF − Capex | $31.1M | — |
| FCF MarginFCF / Revenue | 9.3% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $162.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $36.6M | $43.7M | ||
| Q3 25 | $65.1M | $60.8M | ||
| Q2 25 | $56.9M | $12.0M | ||
| Q1 25 | $27.8M | $35.5M | ||
| Q4 24 | $26.4M | $33.1M | ||
| Q3 24 | $55.4M | $53.9M | ||
| Q2 24 | $989.0K | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $31.1M | $43.5M | ||
| Q3 25 | $60.5M | $57.0M | ||
| Q2 25 | $52.3M | $9.3M | ||
| Q1 25 | $18.7M | $26.9M | ||
| Q4 24 | $21.8M | $31.0M | ||
| Q3 24 | $50.2M | $49.8M | ||
| Q2 24 | $-3.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 9.3% | 22.1% | ||
| Q3 25 | 14.8% | 31.7% | ||
| Q2 25 | 13.1% | 5.1% | ||
| Q1 25 | 5.2% | 15.9% | ||
| Q4 24 | 7.0% | 16.6% | ||
| Q3 24 | 14.3% | 29.6% | ||
| Q2 24 | -1.1% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 0.1% | ||
| Q3 25 | 1.1% | 2.2% | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 2.5% | 5.1% | ||
| Q4 24 | 1.5% | 1.1% | ||
| Q3 24 | 1.5% | 2.4% | ||
| Q2 24 | 1.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | — | ||
| Q3 25 | 1.78× | 11.20× | ||
| Q2 25 | 1.56× | — | ||
| Q1 25 | 1.07× | 7.37× | ||
| Q4 24 | 0.92× | — | ||
| Q3 24 | 2.24× | — | ||
| Q2 24 | 0.03× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLBD
| Alternative Fuel Buses | $151.4M | 45% |
| Diesel Buses | $144.9M | 43% |
| Parts | $24.8M | 7% |
| Other | $12.1M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
